156 related articles for article (PubMed ID: 38924571)
21. Novel silver nanoparticle-antibiotic combinations as promising antibacterial and anti-biofilm candidates against multiple-antibiotic resistant ESKAPE microorganisms.
Mishra M; Ballal A; Rath D; Rath A
Colloids Surf B Biointerfaces; 2024 Apr; 236():113826. PubMed ID: 38447448
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of Antibiotic Resistance of ESKAPE Pathogens Over Five Years in an Infectious Diseases Hospital from South-East of Romania.
Arbune M; Gurau G; Niculet E; Iancu AV; Lupasteanu G; Fotea S; Vasile MC; Tatu AL
Infect Drug Resist; 2021; 14():2369-2378. PubMed ID: 34194233
[TBL] [Abstract][Full Text] [Related]
23. Extent and Resistance Patterns of ESKAPE Pathogens Isolated in Pus Swabs from Hospitalized Patients.
Masoud SS; Kovacevich A; Gangji R; Nyawale H; Nyange M; Ntukula A
Can J Infect Dis Med Microbiol; 2022; 2022():3511306. PubMed ID: 36353409
[TBL] [Abstract][Full Text] [Related]
24. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality.
Ye QF; Zhao J; Wan QQ; Qiao BB; Zhou JD
Transpl Infect Dis; 2014 Oct; 16(5):767-74. PubMed ID: 25124187
[TBL] [Abstract][Full Text] [Related]
25. Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.
Zohra T; Numan M; Ikram A; Salman M; Khan T; Din M; Salman M; Farooq A; Amir A; Ali M
Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946643
[TBL] [Abstract][Full Text] [Related]
26. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
[TBL] [Abstract][Full Text] [Related]
27. Rosin as a Natural Alternative for the effective disinfection of ESKAPE Pathogens and Clostridioides difficile spores.
Bell S; Thompson TP; Marks N; Fairley D; Kettunen H; Vuorenmaa J; Orte J; Gilmore BF; McGrath JW
J Appl Microbiol; 2024 Jan; ():. PubMed ID: 38244225
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
Santajit S; Indrawattana N
Biomed Res Int; 2016; 2016():2475067. PubMed ID: 27274985
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models.
Defraine V; Verstraete L; Van Bambeke F; Anantharajah A; Townsend EM; Ramage G; Corbau R; Marchand A; Chaltin P; Fauvart M; Michiels J
Front Microbiol; 2017; 8():2585. PubMed ID: 29312259
[TBL] [Abstract][Full Text] [Related]
30. 1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.
Deng C; Yan H; Wang J; Liu K; Liu BS; Shi YM
Eur J Med Chem; 2022 Dec; 244():114888. PubMed ID: 36334453
[TBL] [Abstract][Full Text] [Related]
31. Liquid Extraction Surface Analysis Mass Spectrometry of ESKAPE Pathogens.
Havlikova J; May RC; Styles IB; Cooper HJ
J Am Soc Mass Spectrom; 2021 Jun; 32(6):1345-1351. PubMed ID: 33647207
[TBL] [Abstract][Full Text] [Related]
32. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
[TBL] [Abstract][Full Text] [Related]
33. Antipathogenic Efficacy of Biogenic Silver Nanoparticles and Antibiofilm Activities Against Multi-drug-Resistant ESKAPE Pathogens.
Khan MH; Unnikrishnan S; Ramalingam K
Appl Biochem Biotechnol; 2024 Apr; 196(4):2031-2052. PubMed ID: 37462813
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.
Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN
Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396
[TBL] [Abstract][Full Text] [Related]
35. Application of CRISPR-Cas system in the diagnosis and therapy of ESKAPE infections.
Qian Y; Zhou D; Li M; Zhao Y; Liu H; Yang L; Ying Z; Huang G
Front Cell Infect Microbiol; 2023; 13():1223696. PubMed ID: 37662004
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in indole dimers and hybrids with antibacterial activity against methicillin-resistant Staphylococcus aureus.
Meng T; Hou Y; Shang C; Zhang J; Zhang B
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000266. PubMed ID: 32986279
[TBL] [Abstract][Full Text] [Related]
37. An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania.
Peneş NO; Muntean AA; Moisoiu A; Muntean MM; Chirca A; Bogdan MA; Popa MI
Rom J Morphol Embryol; 2017; 58(3):909-922. PubMed ID: 29250670
[TBL] [Abstract][Full Text] [Related]
38.
Escobar-Salom M; Barceló IM; Rojo-Molinero E; Jordana-Lluch E; Cabot G; Oliver A; Juan C
Microbiol Spectr; 2024 Apr; 12(4):e0035824. PubMed ID: 38441982
[TBL] [Abstract][Full Text] [Related]
39. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of community origin of major multidrug-resistant ESKAPE uropathogens in a paediatric population in South-East Gabon.
Mouanga-Ndzime Y; Onanga R; Longo-Pendy NM; Bignoumba M; Bisseye C
Antimicrob Resist Infect Control; 2023 May; 12(1):47. PubMed ID: 37173760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
